Erschienen in:
01.06.2011 | Hepatobiliary Tumors
Medium-Sized HCC: Achieving Effective Local Tumor Control with Combined Chemoebolization and Radiofrequency Ablation
verfasst von:
Eleni Liapi, MD, Jean-Francois H. Geschwind, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 6/2011
Einloggen, um Zugang zu erhalten
Excerpt
Hepatocellular carcinoma (HCC) is the third most important cause of cancer-related mortality worldwide.
1 In the USA, there are approximately 18,000 new HCC cases every year, and HCC incidence and mortality rates continue to increase, particularly among middle-aged Black, Hispanic, and White men.
1 Most patients with HCC present with underlying liver cirrhosis, and therefore any treatment should be focused on these two disease entities concomitantly. Locoregional treatment options such as transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) are minimally invasive treatment options that may individually or in combination address the pertinent issue of successful tumor targeting and preservation of liver function. …